

**ValiRx PLC**  
**("ValiRx" or the "Company")**

**Collaboration Agreement with Voxcell BioInnovation**

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following update from its wholly owned subsidiary Inaphaea BioLabs Limited ("Inaphaea").

Inaphaea is pleased to announce the execution of a collaboration agreement (the "Agreement") with Canada based VoxCell BioInnovation Inc. ("VoxCell") to provide Inaphaea's Patient Derived Cells ("PDC") for evaluation and use in VoxCell's proprietary fully perfusable vascularised 3D tissue culture models. The Agreement initially focusses on establishment of three Triple Negative Breast Cancer ("TNBC") *n-vitro* 3D tumour models which can then be offered for commercial sale and/or services by VoxCell and/or Inaphaea.

As part of the Agreement, three TNBC PDC models will be expanded and tested/optimised for growth on VoxCell's Bioink matrix at Inaphaea's facility. PDCs will then be transferred to VoxCell to generate vascularised 3D cell culture models and further evaluated. Both parties plan to jointly publish the results.

**Mark Eccleston, CEO of ValiRx commented** *"We continue to build partnerships that expand the markets for our PDC models and testing services, particularly in the ex-vivo space considering the FDA's decision to phase out animal-based testing requirements for new drug filings. This Agreement with VoxCell exemplifies our approach to leverage commercial access to our biobank with services and technologies that complement our internal pipeline development and is a real opportunity to develop valuable data to progress our Clx001 oncolytic peptide asset whilst exemplifying the utility of our PDC models in combination with a next generation, non-animal-based testing platform. VoxCell's perfused 3D culture platform is well positioned for testing aspects of nano-formulated drug delivery such as targeting, tumour accumulation from the vasculature and penetration into solid tumours."*

**Karolina Valente, CEO of VoxCell commented** *"We are proud to partner with ValiRx to accelerate the development of physiologically relevant TNBC models. By combining their PDC models with our vascularized 3D bioprinting technology, we will create more predictive, human-like tumour tissues for drug screening. Integrating clinically relevant cells from ValiRx into our high-resolution vascular networks will allow us to support the assessment of ValiRx's Clx001 oncolytic peptide asset in a highly translational environment. This collaboration not only aims to generate valuable efficacy and tumor penetration data for Clx001, but also sets the foundation for expanding our partnership to other cancer indications, leveraging the breadth of ValiRx's PDC model biorepository and VoxCell's advanced, perfused tissue models. Together, we are helping shape a future where complex cancers like TNBC are studied and treated with greater precision and confidence."*

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company take responsibility for this announcement.

**\*\*\* ENDS \*\*\***

Engage with the ValiRx management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here: <https://valirx.com/s/cc8ef3>

For more information, please contact:

<b>Investor questions on this announcement</b>  We encourage all investors to share questions on this announcement via our investor hub	<a href="https://valirx.com/link/aP3wwP">https://valirx.com/link/aP3wwP</a>
<b>ValiRx plc</b>  Dr Mark Eccleston, CEO	<b>Tel: +44 115 784 0026</b>  <a href="http://www.valirx.com">www.valirx.com</a>  Mark.Eccleston@valirx.com
<b>Cairn Financial Advisers LLP (Nominated Adviser)</b>  Liam Murray / Ludovico Lazzaretti	<b>Tel: +44 (0) 20 7213 0880</b>
<b>Shard Capital Partners LLP (Sole Broker)</b>  Damon Heath	<b>Tel: +44 (0) 20 7186 9000</b>

<b>V Formation (Public Relations)</b>	<b>+44 (0) 115 787 0206</b>
Lucy Wharton - Senior PR Executive	<a href="http://www.vformation.biz">www.vformation.biz</a>
Sue Carr - Director	lucy@vformation.biz
	sue@vformation.biz

Subscribe to our news alert service: <https://valirx.com/s/f298d1>

#### Notes for Editors

##### About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: [www.valirx.com](http://www.valirx.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

AGRRPMLTMTATBIA